Europe
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
The Orphazyme board of directors decided to cut 50% of its current global staff count after carefully considering its financial state.
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
Researchers saw that programmed death ligand 1 on dendritic cells could control adaptive immune responses within adipose tissues to limit diet-induced obesity.
Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.
The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.
Kurma Partners earned €160 million in the first closing of its Growth Opportunities fund, and Atlas Venture raked in its largest round of funding yet to invest in new biotech firms.
PRESS RELEASES